Innate Pharma highlights abstracts selected for ASCO 2024 Annual Meeting

• Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab

• Two posters on IPH6501, Innate’s second generation ANKET^®, for the treatment of relapsed/refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma

• AstraZeneca to present poster on updated results for monalizumab from Phase 2 stage III unresectable NSCLC trial

• Monalizumab SCLC Phase 2 MOZART trial poster

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that five abstracts with Innate’s drug candidates have been accepted for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois.

ASCO abstract details:

Lacutamab

• Abstract: 7082
  Abstract Title: Lacutamab in patients with relapsed and/or refractory mycosis fungoides: results from the TELLOMAK Phase 2 trial
  First Author: Pierluigi Porcu
  Session Type: Poster Session
  Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
  Session Date and Time: Monday June 3, 2024 – 9:00 AM – 12:00 PM

   

IPH6501

• Abstract: TPS7095
  Abstract Title: A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients With Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
  First Author: Lorenzo Falchi
  Session Type: Poster Session
  Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
  Session Date and Time: Monday June 3, 2024 – 9:00 AM – 12:00 PM

   

• Abstract: 7030
  Abstract Title: Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK Cell Engager directed against CD20 for R/R B-NHL, in comparison to a CD20-targeting T Cell Engager
  First Author: Olivier Demaria
  Session Type: Poster Session
  Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
  Session Date and Time: Monday June 3, 2024 – 9:00 AM – 12:00 PM

   

Monalizumab (partnered with AstraZeneca)

• Abstract: 8046
  Abstract Title: Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC)
  First Author: Charu Aggarwal
  Session Type: Poster Session
  Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
  Session Date and Time: Monday June 3, 2024 – 1:30 PM – 4:30 PM

   

• Abstract: TPS8129
  Abstract Title: A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study.
  First Author: Hirva Mamdani
  Session Type: Poster Session
  Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
  Session Date and Time: Monday June 3, 2024 – 1:30 PM – 4:30 PM